Precultured with OVA, modified DEXs activated T cells via MHC-antigen peptide complexes and CD86 costimulatory molecules and acted as a bridge between cancer cells and T cells by simultaneously targeting T cell surface CD3 and EGFR on cancer cells. The gene discussed is CD86; the disease is cancer.